[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Gezondheid en geneeskundeOne-Off3jManifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige gemeenschapsvoorspelling2030 36.4%Koploper van 6 uitkomsten
Voorspellers
21
Vraagtype
multiple choice
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
7d wijziging
0.0 pts
Marktdata
Bijgewerkt 1 uur geleden
Vertraagd18 nov 23, 22:14 UTC1 jan 30, 04:59 UTC
Trends
Regels
Inspired by https://manifold.markets/AaronKaufman/will-any-fdaapproved-glp1-agonists and will use the same criteria:
- GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment.
- This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date.
- This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
